^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IL-2R agonist

    Related drugs:
    1m
    Neo-DREAM: Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients (clinicaltrials.gov)
    P3, N=186, Recruiting, Philogen S.p.A. | Trial completion date: Jun 2026 --> Dec 2031 | Trial primary completion date: Jun 2024 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Nidlegy (darleukin/fibromun)
    2ms
    A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=189, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | Trial completion date: Aug 2026 --> Oct 2025 | Trial primary completion date: Jan 2026 --> Oct 2025
    Trial completion • Trial completion date • Trial primary completion date • Tumor mutational burden • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • eciskafusp alfa (RG6279)
    2ms
    L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=92, Not yet recruiting, Philogen S.p.A.
    New P2 trial
    |
    Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
    2ms
    L19IL2/TNF in Patients With Basal Cell Carcinoma (clinicaltrials.gov)
    P2, N=92, Not yet recruiting, Philogen S.p.A.
    New P2 trial
    |
    Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
    2ms
    L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC) (clinicaltrials.gov)
    P2, N=180, Not yet recruiting, Philogen S.p.A.
    New P2 trial
    |
    Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
    4ms
    PD-1-Cis IL-2R Agonism Determines the Predicted Pharmacological Dose Range for the Immunocytokine Eciskafusp Alfa (PD1-IL2v). (PubMed, CPT Pharmacometrics Syst Pharmacol)
    Furthermore, binding in cis-configuration is expected to follow a "bell-shaped" relationship with drug concentration such that high concentrations may lead to reduced benefit/risk ratio compared with concentrations around the peak of the bell-shape. Model simulations identify patient cohorts for whom the upper limit of the pharmacological dosing range may be defined by either undesirable off-tumor target engagement or a decrease in on-tumor cis-binding.
    Journal
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IL2RA (Interleukin 2 receptor, alpha)
    |
    eciskafusp alfa (RG6279)
    5ms
    Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) (clinicaltrials.gov)
    P3, N=456, Terminated, Mural Oncology, Inc | Trial completion date: May 2027 --> May 2025 | Active, not recruiting --> Terminated | Trial primary completion date: May 2026 --> Jan 2025; Study terminated due to business and strategic decision.
    Trial completion date • Trial termination • Trial primary completion date • Platinum resistant
    |
    Keytruda (pembrolizumab) • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • Myocet (non-pegylated liposomal doxorubicin) • nemvaleukin alfa (ALKS 4230)
    5ms
    Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus (clinicaltrials.gov)
    P2, N=66, Not yet recruiting, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    New P2 trial
    6ms
    Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial. (PubMed, J Immunother Cancer)
    Nemvaleukin demonstrated pharmacodynamic proof of mechanism, with single-agent antitumor activity and manageable safety in patients with advanced melanoma and RCC.
    P1/2 data • Journal
    |
    CD8 (cluster of differentiation 8)
    |
    Keytruda (pembrolizumab) • nemvaleukin alfa (ALKS 4230)
    6ms
    BelieveIT-201: TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=27, Terminated, Ascendis Pharma A/S | Trial primary completion date: Dec 2024 --> Mar 2025
    Trial primary completion date
    |
    Keytruda (pembrolizumab) • onvapegleukin alfa (TransCon IL-2 β/γ) • resiquimod SR (TransCon TLR7/8 Agonist)
    6ms
    ANV600 is a novel PD-1 targeted IL-2Rβγ agonist that selectively expands tumor antigen-specific T cells and potentiates PD-1 checkpoint inhibitor therapy. (PubMed, J Immunother Cancer)
    ANV600 represents a novel approach to delivering IL-2Rβγ agonism specifically to PD-1+ cells while preserving the binding site for PD-1 checkpoint inhibitors. By targeting a non-blocking epitope on PD-1, ANV600 enables the selective expansion of tumor-reactive CD8+ T cells while allowing independent and optimized dosing of both agents. This design ensures combinability with PD-1 inhibitors at clinically relevant doses, including in patients previously treated with checkpoint blockade. These findings support the clinical development of ANV600 as both a monotherapy and a combination therapy in cancer immunotherapy.
    Journal • Checkpoint inhibition
    |
    CD8 (cluster of differentiation 8) • IL2 (Interleukin 2)
    |
    BRAF V600
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • fingolimod
    7ms
    BelieveIT-201: TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=27, Terminated, Ascendis Pharma A/S | Completed --> Terminated; The Sponsor made the decision to close enrollment as part of a strategic portfolio review.
    Trial termination
    |
    Keytruda (pembrolizumab) • onvapegleukin alfa (TransCon IL-2 β/γ) • resiquimod SR (TransCon TLR7/8 Agonist)